LS offers comprehensive and independent coverage of drug pricing, reimbursement and market access trends, as well as healthcare forecasts and healthcare economic data microsimulation modelling.
The terms of the deal were not disclosed, completion is expected to occur during Q4 of 2021 and will be funded from the Group’s existing cash resources and banking facilities.
Commenting on the acquisition Mike Danson, Chief Executive Officer, said: “The Life Sciences acquisition represents a strategic bolt-on to our already strong pharmaceuticals data, insights and analytics services. The addition of drug pricing data, as well as other critical Life Sciences data and analysis, further confirms our industry leading breadth and depth in the pharmaceuticals space.
I would like to take this opportunity to welcome our new group of highly talented colleagues to the Group and wish them every success for the future within GlobalData”
Gustav Ando, Vice President and Head of Life Sciences at IHS Markit, added: “We are looking forward to becoming an integral part of the GlobalData Pharma and Life Sciences Team. This unique combination will enable us to provide our current and expanded client base with a much broader service offering, through synergy with existing GlobalData services, and on a single fully integrated platform.”